{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FLARE&page=2", "query": { "intervention": "FLARE", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FLARE&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T12:43:11.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04130204", "title": "Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "DYV700", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Colchicine 0.6 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dyve Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 284, "start_date": "2020-02-12", "completion_date": "2021-05-21", "has_results": false, "last_update_posted_date": "2022-05-13", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 1, "location_summary": "Poway, California", "locations": [ { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04130204" }, { "nct_id": "NCT00000421", "title": "Serologically Active, Clinically Stable Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "13 Years to 65 Years · Female only" }, "enrollment_count": 154, "start_date": "1997-09", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2016-03-04", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 3, "location_summary": "New Hyde Park, New York • New York, New York • The Bronx, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000421" }, { "nct_id": "NCT01781611", "title": "Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "extended release dipyridamole 200mg/aspirin 25mg", "type": "DRUG" }, { "name": "81mg aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oklahoma Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2013-02", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01781611" }, { "nct_id": "NCT02939573", "title": "A Randomized Multicenter Study for Isolated Skin Vasculitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Cutaneous Vasculitis", "Cutaneous Polyarteritis Nodosa", "IgA Vasculitis", "Henoch-Schönlein Purpura" ], "interventions": [ { "name": "Colchicine", "type": "DRUG" }, { "name": "Dapsone", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-01-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 12, "location_summary": "Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02939573" }, { "nct_id": "NCT00495521", "title": "High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "4-Aminosalicylic acid extended release granules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobus Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 2, "start_date": "2007-06", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2017-09-21", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00495521" }, { "nct_id": "NCT06616363", "title": "Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities?", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "POTS - Postural Orthostatic Tachycardia Syndrome" ], "interventions": [ { "name": "Questionnaires to be competed", "type": "BEHAVIORAL" }, { "name": "Provide list of medication and lifetime events", "type": "BEHAVIORAL" }, { "name": "Use phone App to record new life events", "type": "BEHAVIORAL" }, { "name": "Will wear an activity monitor", "type": "DEVICE" }, { "name": "Periodic 24-hour urine sodium check", "type": "OTHER" }, { "name": "A fMRI scan", "type": "DIAGNOSTIC_TEST" }, { "name": "A bedside tilt test will be performed", "type": "DIAGNOSTIC_TEST" }, { "name": "IV placed to collect blood samples", "type": "OTHER" }, { "name": "Stool Sample", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "21 Years", "sex": "FEMALE", "summary": "12 Years to 21 Years · Female only" }, "enrollment_count": 120, "start_date": "2024-05-29", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06616363" }, { "nct_id": "NCT03426384", "title": "FLARE Lupus Research Study Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "System; Lupus Erythematosus" ], "interventions": [ { "name": "Mymee Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Mymee Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-02-12", "completion_date": "2019-12-05", "has_results": false, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03426384" }, { "nct_id": "NCT05316584", "title": "A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Diseases", "Crohn Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Remote monitoring", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 123, "start_date": "2022-09-06", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 5, "location_summary": "Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316584" }, { "nct_id": "NCT03325166", "title": "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Carcinoma Metastatic in the Brain", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-11-03", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03325166" }, { "nct_id": "NCT04435600", "title": "A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 139, "start_date": "2020-07-14", "completion_date": "2024-10-15", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-09-18T12:43:11.767Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435600" } ] }